Sonrotoclax

SKU: orb1982765

Description

Sonrotoclax (BGB-11417) is a potent and selective Bcl-2 inhibitor active against both wild-type and the G101V mutant protein. This investigational small molecule demonstrates antitumor activity in preclinical models of hematological malignancies, supporting its research in leukemia and lymphoma, including in vitro cellular assays and in vivo xenograft studies.

Research Area

Cell Biology

Key Properties

• CAS Number: 2383086-06-2
• MW: 890.10
• Purity: 99.47% (May vary between batches)
• Formula: C₄₉H₅₉N₇O₇S
• SMILES: CC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC([N+]([O-])=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C
• Target: Bcl-2 Family
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (3.71 mM);DMSO:80 mg/mL (89.88 mM)

Bioactivity

• In Vivo:
  In Female NCG mice with acute lymphoblastic leukemia ( ALL ) xenografts, Sonrotoclax ( 5,15,50 mg / kg ; oral administration ; daily, for 42 days ) can inhibit tumor growth in a dose-dependent manner.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BGB 11417, Bcl-2

Compound Identifiers

PubChem CID

149553242